Operating Lease, Right-of-Use Asset of Kalaris Therapeutics, Inc. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Kalaris Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • Kalaris Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $1,516,000.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Kalaris Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,516,000 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q4 2024 $0 -$2,187,000 -100% 31 Dec 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $495,000 -$26,990,000 -98% 30 Jun 2024 10-Q 09 Aug 2024 2024 Q2
Q1 2024 $2,107,000 -$27,476,000 -93% 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 $2,187,000 -$29,446,000 -93% 31 Dec 2023 10-K 07 Mar 2025 2024 FY
Q3 2023 $25,343,000 +$6,216,000 +32% 30 Sep 2023 10-Q 02 Nov 2023 2023 Q3
Q2 2023 $27,485,000 +$6,713,000 +32% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $29,583,000 +$7,848,000 +36% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $31,633,000 +$1,890,000 +6.4% 31 Dec 2022 10-K 15 Mar 2024 2023 FY
Q3 2022 $19,127,000 -$12,360,000 -39% 30 Sep 2022 10-Q 03 Nov 2022 2022 Q3
Q2 2022 $20,772,000 +$11,213,000 +117% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $21,735,000 +$10,987,000 +102% 31 Mar 2022 10-Q 05 May 2022 2022 Q1
Q4 2021 $29,743,000 +$21,051,000 +242% 31 Dec 2021 10-K 15 Feb 2023 2022 FY
Q3 2021 $31,487,000 +$22,013,000 +232% 30 Sep 2021 10-Q 05 Nov 2021 2021 Q3
Q2 2021 $9,559,000 -$686,000 -6.7% 30 Jun 2021 10-Q 06 Aug 2021 2021 Q2
Q1 2021 $10,748,000 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 $8,692,000 -$3,067,000 -26% 31 Dec 2020 10-K 10 Feb 2022 2021 FY
Q3 2020 $9,474,000 30 Sep 2020 10-Q 10 Nov 2020 2020 Q3
Q2 2020 $10,245,000 30 Jun 2020 10-Q 02 Sep 2020 2020 Q2
Q4 2019 $11,759,000 31 Dec 2019 10-K 12 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.